Clinical & Scientific

After clearing the EU's rigorous MDR hurdle, P&F's novel heart valve system secures its European future and sets its sights on the lucrative US market.

A new partnership aims to overcome the hurdles of at-home testing by combining instrument-free PCR with advanced enzymes for rapid, reliable results.

CoSara Diagnostics' ISO 13485 certification paves the way for regulatory approval of a new PCR platform, leveraging India's 'Make in India' initiative.

New 4-year real-world data shows Zevra's drug stabilizes the rare, fatal 'Childhood Alzheimer's' disease, marking a milestone for patients and families.

With a key cancer drug awaiting FDA review and pivotal data imminent, Celcuity faces investors at a critical juncture. What will they be looking for?

A new class of compounds 'disarms' TB bacteria instead of killing it, a breakthrough that could help defeat drug resistance and treat the world's deadliest disease.

A major multi-vendor study confirms AI's power for precision HER2 scoring, promising to improve diagnostics and accelerate personalized cancer therapies.

With an extra $3M, Aduro Clean Technologies advances its game-changing plant, turning investor confidence into a reality for recycling and energy.

With a major cash infusion, NeOnc Technologies is set to accelerate its promising therapies aimed at conquering the elusive blood-brain barrier.

Ruxolitinib cream's landmark approval in China marks a new era for vitiligo treatment, impacting patients, markets, and regulatory policy.

Top scientists, survivors, and industry leaders are uniting to accelerate a new generation of cancer vaccines, moving them from lab to patient faster than ever.

Following impressive Phase 2 results, Scancell's novel immunotherapy iSCIB1+ receives FDA clearance for a pivotal trial, offering new hope for patients.

A new partnership aims to accelerate a pipeline of innovative multi-functional fusion proteins, potentially reshaping treatment for cancer and autoimmune disease.

London's Ellipses Pharma in-licenses a novel B7H3 antibody-drug conjugate from Innolake, aiming to outmaneuver competitors with a unique payload.

PulseSight's first-in-class gene therapy for dry AMD completes its Phase I trial, offering a novel approach to a leading cause of vision loss.

A new partnership aims to accelerate mental health innovation by combining a national research network with deep community-based expertise in CNS trials.

With a new CEO and promising data, Emmecell aims to replace corneal transplants with its magnetic cell delivery platform. But can it win in a competitive market?

Vaximm appoints Sébastien Wieckowski as CSO, leveraging his data science expertise to advance its oral cancer vaccine platform at a pivotal clinical stage.

Backed by Canada's life sciences engine adMare, new biotech firm Ocythera is advancing a unique non-retinoid therapy for debilitating bone disorders.

Cardiac Biotech Solutions partners with a local firm to launch its MyCardia AT monitor in China's booming, nearly $3 billion cardiac device market.